261 related articles for article (PubMed ID: 24475985)
1. Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis.
Zhang Z; Ni C; Chen W; Wu P; Wang Z; Yin J; Huang J; Qiu F
BMC Cancer; 2014 Jan; 14():49. PubMed ID: 24475985
[TBL] [Abstract][Full Text] [Related]
2. The association of CXCR4 expression with clinicopathological significance and potential drug target in prostate cancer: a meta-analysis and literature review.
Chen Q; Zhong T
Drug Des Devel Ther; 2015; 9():5115-22. PubMed ID: 26379424
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological and prognostic value of CD24 expression in breast cancer: a meta-analysis.
Liu G; Liu GX; Fang Y; Cao ZY; Du HH; Fu J; Qian K
Int J Biol Markers; 2017 May; 32(2):e182-e189. PubMed ID: 28315505
[TBL] [Abstract][Full Text] [Related]
4. The impact of chemokine receptor CXCR4 on breast cancer prognosis: a meta-analysis.
Xu TP; Shen H; Liu LX; Shu YQ
Cancer Epidemiol; 2013 Oct; 37(5):725-31. PubMed ID: 23763828
[TBL] [Abstract][Full Text] [Related]
5. Role of CXCR4 and SDF1 as prognostic factors for survival and the association with clinicopathology in colorectal cancer: A systematic meta-analysis.
Li YP; Pang J; Gao S; Bai PY; Wang WD; Kong P; Cui Y
Tumour Biol; 2017 Jun; 39(6):1010428317706206. PubMed ID: 28621237
[TBL] [Abstract][Full Text] [Related]
6. Worse outcome in breast cancer with higher tumor-infiltrating FOXP3+ Tregs : a systematic review and meta-analysis.
Shou J; Zhang Z; Lai Y; Chen Z; Huang J
BMC Cancer; 2016 Aug; 16(1):687. PubMed ID: 27566250
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological and prognostic significance of chemokine receptor CXCR4 overexpression in patients with esophageal cancer: a meta-analysis.
Wu J; Wu X; Liang W; Chen C; Zheng L; An H
Tumour Biol; 2014 Apr; 35(4):3709-15. PubMed ID: 24326770
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and clinicopathological value of Twist expression in breast cancer: A meta-analysis.
Qiao W; Jia Z; Liu H; Liu Q; Zhang T; Guo W; Li P; Deng M; Li S
PLoS One; 2017; 12(10):e0186191. PubMed ID: 29016671
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis.
Pan F; Mao H; Deng L; Li G; Geng P
Int J Clin Exp Pathol; 2014; 7(9):5622-33. PubMed ID: 25337203
[TBL] [Abstract][Full Text] [Related]
10. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
11. The association of CXCR4 expression with prognosis and clinicopathological indicators in colorectal carcinoma patients: a meta-analysis.
Lv S; Yang Y; Kwon S; Han M; Zhao F; Kang H; Dai C; Wang R
Histopathology; 2014 Apr; 64(5):701-12. PubMed ID: 24422942
[TBL] [Abstract][Full Text] [Related]
12. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.
Salvucci O; Bouchard A; Baccarelli A; Deschênes J; Sauter G; Simon R; Bianchi R; Basik M
Breast Cancer Res Treat; 2006 Jun; 97(3):275-83. PubMed ID: 16344916
[TBL] [Abstract][Full Text] [Related]
13. Correlation effect of EGFR and CXCR4 and CCR7 chemokine receptors in predicting breast cancer metastasis and prognosis.
Liu Y; Ji R; Li J; Gu Q; Zhao X; Sun T; Wang J; Li J; Du Q; Sun B
J Exp Clin Cancer Res; 2010 Feb; 29(1):16. PubMed ID: 20181250
[TBL] [Abstract][Full Text] [Related]
14. The clinicopathological and prognostic value of CXCR4 expression in patients with lung cancer: a meta-analysis.
Qiu L; Xu Y; Xu H; Yu B
BMC Cancer; 2022 Jun; 22(1):681. PubMed ID: 35729596
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological and prognostic significance of COX-2 immunohistochemical expression in breast cancer: a meta-analysis.
Xu F; Li M; Zhang C; Cui J; Liu J; Li J; Jiang H
Oncotarget; 2017 Jan; 8(4):6003-6012. PubMed ID: 27999206
[TBL] [Abstract][Full Text] [Related]
16. Neuropilin-2 expression in breast cancer: correlation with lymph node metastasis, poor prognosis, and regulation of CXCR4 expression.
Yasuoka H; Kodama R; Tsujimoto M; Yoshidome K; Akamatsu H; Nakahara M; Inagaki M; Sanke T; Nakamura Y
BMC Cancer; 2009 Jul; 9():220. PubMed ID: 19580679
[TBL] [Abstract][Full Text] [Related]
17. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer.
Paik S; Bryant J; Park C; Fisher B; Tan-Chiu E; Hyams D; Fisher ER; Lippman ME; Wickerham DL; Wolmark N
J Natl Cancer Inst; 1998 Sep; 90(18):1361-70. PubMed ID: 9747867
[TBL] [Abstract][Full Text] [Related]
18. The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients.
Parker CC; Kim RH; Li BD; Chu QD
J Surg Oncol; 2012 Sep; 106(4):393-8. PubMed ID: 22473623
[TBL] [Abstract][Full Text] [Related]
19. A meta-analysis for C-X-C chemokine receptor type 4 as a prognostic marker and potential drug target in hepatocellular carcinoma.
Hu F; Miao L; Zhao Y; Xiao YY; Xu Q
Drug Des Devel Ther; 2015; 9():3625-33. PubMed ID: 26203228
[TBL] [Abstract][Full Text] [Related]
20. Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis.
Yasuoka H; Tsujimoto M; Yoshidome K; Nakahara M; Kodama R; Sanke T; Nakamura Y
BMC Cancer; 2008 Nov; 8():340. PubMed ID: 19025611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
